164 related articles for article (PubMed ID: 36270741)
1. Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening.
Xu T; Chen Z; Jiang M; Ma H; Jin K; Wang Z; Wang C; Xu J; Zhang W
RMD Open; 2022 Oct; 8(2):. PubMed ID: 36270741
[TBL] [Abstract][Full Text] [Related]
2. Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study.
Mendel A; Behlouli H; de Moura CS; Vinet É; Curtis JR; Bernatsky S
Arthritis Res Ther; 2023 Jul; 25(1):133. PubMed ID: 37516897
[TBL] [Abstract][Full Text] [Related]
3. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis.
Monti S; Delvino P; Riboli M; Rebuffi C; Xoxi B; De Silvestri A; Montecucco C
Rheumatology (Oxford); 2021 Aug; 60(8):3553-3564. PubMed ID: 33752235
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis.
Waki D; Nishimura K; Yoshida T; Tanaka N; Mizukawa K; Fukushima M; Iri O; Anegawa M; Murabe H; Yokota T
Clin Exp Rheumatol; 2021; 39 Suppl 129(2):142-148. PubMed ID: 33734974
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for serious infections in ANCA-associated vasculitis.
Odler B; Riedl R; Gauckler P; Shin JI; Leierer J; Merkel PA; St Clair W; Fervenza F; Geetha D; Monach P; Jayne D; Smith RM; Rosenkranz A; Specks U; Stone JH; Kronbichler A;
Ann Rheum Dis; 2023 May; 82(5):681-687. PubMed ID: 36702528
[TBL] [Abstract][Full Text] [Related]
6. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.
Kronbichler A; Kerschbaum J; Gopaluni S; Tieu J; Alberici F; Jones RB; Smith RM; Jayne DRW
Ann Rheum Dis; 2018 Oct; 77(10):1440-1447. PubMed ID: 29950327
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
8. Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis.
Yoo J; Jung SM; Song JJ; Park YB; Lee SW
Clin Rheumatol; 2018 Aug; 37(8):2133-2141. PubMed ID: 29557539
[TBL] [Abstract][Full Text] [Related]
9. The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study.
Fonseca JA; Gameiro J; Duarte I; Jorge S; Lopes JA
Nefrologia (Engl Ed); 2021; 41(3):321-328. PubMed ID: 36165341
[TBL] [Abstract][Full Text] [Related]
10. Infectious profile in inpatients with ANCA-associated vasculitis: a single-center retrospective study from Southern China.
Lao M; Huang M; Li C; Li H; Qiu Q; Zhan Z; Chen D
Clin Rheumatol; 2020 Feb; 39(2):499-507. PubMed ID: 31576488
[TBL] [Abstract][Full Text] [Related]
11. Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients.
Lhote R; Chilles M; Groh M; Puéchal X; Guilpain P; Ackermann F; Amoura Z; Annesi-Maesano I; Barba T; Catherinot E; Cohen-Aubart F; Cohen P; Cottin V; Couderc LJ; De Boysson H; Delbrel X; Dominique S; Duhaut P; Fain O; Hachulla E; Hamidou M; Kahn JE; Legendre C; Le Quellec A; Lhote F; Lifermann F; Mathian A; Néel A; Nunes H; Subra JF; Terrier B; Mouthon L; Diot E; Guillevin L; Brillet PY; Tcherakian C;
J Rheumatol; 2020 Oct; 47(10):1522-1531. PubMed ID: 31787599
[TBL] [Abstract][Full Text] [Related]
12. Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study.
Yoo BW; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
Clin Rheumatol; 2020 Mar; 39(3):831-840. PubMed ID: 31802348
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.
Yang L; Xie H; Liu Z; Chen Y; Wang J; Zhang H; Ge Y; Hu W
BMC Nephrol; 2018 Jun; 19(1):138. PubMed ID: 29902982
[TBL] [Abstract][Full Text] [Related]
14. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and the Risk of Developing Incidental Tuberculosis: A Population-Based Cohort Study.
Chan SH; Li MF; Ou SH; Lin MC; Wang JH; Lee PT; Chen HY
Medicina (Kaunas); 2023 Oct; 59(11):. PubMed ID: 38003970
[No Abstract] [Full Text] [Related]
15. The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study.
Fonseca JA; Gameiro J; Duarte I; Jorge S; Lopes JA
Nefrologia (Engl Ed); 2021; 41(3):321-328. PubMed ID: 33309337
[TBL] [Abstract][Full Text] [Related]
16. The Association of Airway Comorbidities With the Clinical Phenotypes and Outcomes of Patients With Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis.
Ono N; Inoue Y; Miyamura T; Ueda N; Nagano S; Inoue H; Oryoji K; Ota SI; Sawabe T; Yoshizawa S; Takeyama Y; Sadanaga Y; Takamori A; Kimoto Y; Miyake K; Horiuchi T; Nakashima H; Niiro H; Tada Y
J Rheumatol; 2021 Mar; 48(3):417-425. PubMed ID: 31523048
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Risk Factors for Major Infections in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Influence on the Disease Outcome.
Garcia-Vives E; Segarra-Medrano A; Martinez-Valle F; Agraz I; Solans-Laque R
J Rheumatol; 2020 Mar; 47(3):407-414. PubMed ID: 31203229
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature.
Comarmond C; Crestani B; Tazi A; Hervier B; Adam-Marchand S; Nunes H; Cohen-Aubart F; Wislez M; Cadranel J; Housset B; Lloret-Linares C; Sève P; Pagnoux C; Abad S; Camuset J; Bienvenu B; Duruisseaux M; Hachulla E; Arlet JB; Hamidou M; Mahr A; Resche-Rigon M; Brun AL; Grenier P; Cacoub P; Saadoun D
Medicine (Baltimore); 2014 Nov; 93(24):340-349. PubMed ID: 25500703
[TBL] [Abstract][Full Text] [Related]
19. Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis.
Cohen Tervaert JW
Curr Opin Rheumatol; 2018 Jul; 30(4):388-394. PubMed ID: 29621029
[TBL] [Abstract][Full Text] [Related]
20. Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis.
McAdoo SP; Hall A; Levy J; Salama AD; Pusey CD
J Clin Rheumatol; 2012 Oct; 18(7):336-40. PubMed ID: 23047533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
